Journal of pharmacy practice最新文献

{"title":"Utility of Pre-operative P2Y12 Levels for Perioperative Bleeding Risk in Isolated Coronary Artery Bypass Surgery.","authors":"Crystal Li, Joshua L Leibowitz, Justin Robinson, Stephen Stachnik, Alison Grazioli, Douglas Anderson, Michael E Plazak, Reney A Henderson, Bradley S Taylor, Aakash Shah","doi":"10.1177/08971900261477838","DOIUrl":"https://doi.org/10.1177/08971900261477838","url":null,"abstract":"<p><p>A retrospective review of patients at a single institution who underwent isolated coronary artery bypass (CABG) surgery between 2017 and 2023 was conducted to investigate the clinical utility of pre-operatively measuring platelet inhibition as a predictor of bleeding complications, especially in the context of bypass surgery. Patients who underwent CABG procedure and were on P2Y12 inhibitors such as clopidogrel or ticagrelor preoperatively and had preoperative P2Y12 platelet reactivity unit (PRU) level measured. Patients were stratified by a PRU <200 or ≥200. In both groups, patients were divided into patients who took clopidogrel and patients who took ticagrelor. There were 189 patients included in the study. Patients with a PRU ≥200 were of similar age and comorbidities to those with a PRU <200, however, more were female. Both groups had a similar mean duration of days since last P2Y12 inhibitor dose prior to surgery. There were greater intraoperative platelet transfusions in the PRU <200 group (mean 0.7 vs 0.3 units, <i>P</i> = 0.001). Intraoperative red blood cell and plasma transfusion and postoperative transfusions, 24-hour chest tube output, and re-exploration for bleeding were similar between the groups. There were no differences in bleeding complications between pharmacologic agent in either group. Our findings suggest that preoperative assessment of P2Y12 PRU may have limited clinical utility at a cutoff of 200 in predicting bleeding in patients undergoing CABG. Patients with PRU <200 received higher rates of platelet transfusion, without differences in other blood products.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477838"},"PeriodicalIF":1.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Sequential Nephron Blockade Compared to Standard Loop Diuretic for Fluid De-resuscitation in the ICU.","authors":"Noelle Brittain, Megan Van Berkel Patel, Lauren Caldwell, Andrew Shine, Jeremy Greenberg, Jessica Parker, Nolan Rossman, Jessica Briscoe","doi":"10.1177/08971900261477835","DOIUrl":"https://doi.org/10.1177/08971900261477835","url":null,"abstract":"<p><p>Diuretics are integral in fluid de-resuscitation of ICU patients following initial stabilization. While loop diuretics are commonly used, sequential nephron blockade (SNB) is an alternative diuretic strategy that combines a loop diuretic with at least one diuretic from another pharmacologic class to increase efficacy and limit adverse effects. The objective of this study was to compare the safety and efficacy of SNB to loop diuretics alone for de-resuscitation of critically ill patients. This retrospective study included adult ICU patients who received either a loop diuretic alone or combined with an aldosterone antagonist, carbonic anhydrase inhibitor, and/or thiazide diuretic on two consecutive days. The primary outcome was comparison of diuretic efficacy, assessed by urine output, on diuresis day 1. Secondary outcomes included comparison of diuretic efficacy on diuresis days 2-5 and incidence of acute kidney injury and electrolyte abnormalities on diuresis day 1. A total of 100 patients were included (SNB = 15, Loop = 85). At baseline, SNB patients had more hypernatremia (20% vs 2.4%, <i>P</i> = 0.023) and hyperchloremia (20% vs 2.4%, <i>P</i> = 0.023). Patients in the SNB group had increased urine output on diuresis day 1 (4725 vs 2215 mL, <i>P</i> = 0.0004). AKI did not occur in SNB patients on diuresis day 1 vs 15.5% of loop patients (<i>P</i> = 0.208). Hypernatremia (26.7% vs 2.4%, <i>P</i> = 0.004) and hyperchloremia (13.3% vs 3.5%, <i>P</i> = 0.161), persisted in the SNB group on diuretic day 2. In conclusion, among ICU patients requiring de-resuscitation, SNB may be associated with improved diuresis and similar safety concerns compared to loop diuretics alone.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"8971900261477835"},"PeriodicalIF":1.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olmesartan-Induced Enteropathy: Case Reports and Insights From FDA Adverse Event Reporting System (FAERS).","authors":"Ilaria Mariani, Giulia Mosini, Stefania Cheli, Sofia Dinegro, Andrea Vicenzi, Cecilia Bonino, Vera Battini, Carla Carnovale, Emilio Clementi, Sonia Radice","doi":"10.1177/08971900251376797","DOIUrl":"10.1177/08971900251376797","url":null,"abstract":"<p><p>Olmesartan, an angiotensin II receptor blocker (ARB) approved in 2002, is used to treat hypertension, either alone or with other antihypertensive drugs. It has been frequently associated with sprue-like enteropathy, while few cases of colitis have been reported. Differentiating between sprue-like enteropathy and colitis is of clinical concern, since just the first condition is a well-documented adverse event of olmesartan. Diagnosis of these occurrences is difficult, as symptoms are unspecific namely diarrhoea, weight loss, fatigue, nausea, and abdominal discomfort, with laboratory findings showing anaemia, electrolyte imbalances, and vitamin deficiencies. Here, we report two cases of patients in treatment for hypertension with olmesartan in association with hydrochlorothiazide and amlodipine, who developed sprue-like enteropathy and colitis, respectively. We then conducted a disproportionality analysis of cases retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to assess the association level between these conditions and olmesartan. We found a strong association between olmesartan and sprue-like enteropathy (ROR 8499.53 (95% CI: 8402.05 - 16383.99)). Olmesartan resulted to be associated also with colitis (ROR 2.56 (95% CI: 2.28 - 2.88)). In light of the diagnostic challenges posed by nonspecific symptoms, these findings underscore the importance of distinguishing between the two conditions in patients exposed to olmesartan, to improve the spectrum of knowledge.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"342-347"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Ibuprofen Versus Intramuscular Ketorolac for Acute Musculoskeletal Back Pain in the Emergency Department: A Prospective Analysis.","authors":"Myroslava Sharabun, Robert O'Connell, Howard Greller, Andrew P Smith","doi":"10.1177/08971900251394098","DOIUrl":"10.1177/08971900251394098","url":null,"abstract":"<p><p>Ibuprofen and ketorolac are nonsteroidal anti-inflammatory drugs (NSAIDs) commonly used to treat acute back pain in the Emergency Department (ED). Data comparing pain relief between oral and intramuscular administration at their proposed ceiling doses is lacking. The aim of this study was to compare oral (PO) ibuprofen 400 mg to intramuscular (IM) ketorolac 10 mg for the treatment of acute, atraumatic, musculoskeletal back pain. This single-center, double-blind, double-placebo, randomized study compared PO ibuprofen 400 mg to IM ketorolac 10 mg for acute, atraumatic musculoskeletal back pain in adult patients presenting to an urban ED. Subjects were randomized to receive PO ibuprofen 400 mg suspension plus IM placebo injection or IM ketorolac 10 mg plus PO placebo suspension. The primary outcome was absolute reduction in pain score 1 hour after medication administration, as measured by visual analog scale (VAS). Secondary outcomes included rescue analgesia administration at 60 minutes and adverse drug reactions. The author's enrolled 93 patients; 47 in the ibuprofen group and 46 in the ketorolac group. VAS score reduction from baseline to 1 hour with ibuprofen or ketorolac was 35 vs 32, respectively (95% Confidence Interval: -8.03 to 15.03). Rescue analgesia administration at 60 minutes was similar between both groups; adverse reactions were reported in the ketorolac group only as pain at injection site in two patients. In this prospective analysis, PO ibuprofen 400 mg and IM ketorolac 10 mg provide comparable pain relief for the treatment of acute, atraumatic, musculoskeletal back pain.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"315-321"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aripiprazole-Induced Hyponatremia Observed Upon Rechallenge: A Case Report.","authors":"Nicholas McGuire, Leslie Wu, Archana Jhawar","doi":"10.1177/08971900251394100","DOIUrl":"10.1177/08971900251394100","url":null,"abstract":"<p><p>Medications account for nearly two-thirds of all cases of syndrome of inappropriate antidiuretic hormone secretion (SIADH). Numerous psychotropics including antipsychotics have been associated with SIADH but it is difficult to show a causal relationship. We report a unique case where a patient developed hyponatremia and upon rechallenge with aripiprazole resulted in a second incidence. There is limited literature recognizing aripiprazole induced SIADH and especially any focused on medication rechallenge.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"348-354"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145390552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of Empiric Antimicrobial Therapy for Community Onset Sepsis With Bacteremia in the Emergency Department: A Multidisciplinary Approach.","authors":"Salma Abdelwahab, Yanina Dubrovskaya, Kassandra Marsh, Cristian Merchan, Samantha Smalley, Justin Siegfried, John Papadopoulos","doi":"10.1177/08971900251394125","DOIUrl":"10.1177/08971900251394125","url":null,"abstract":"<p><p><b>Background:</b> Optimizing early antimicrobial therapy and incorporating clinical pharmacists into sepsis treatment strategies are essential for improving patient outcomes. <b>Objective:</b> To examine the appropriateness of empiric antimicrobial selection for patients presenting with community onset sepsis with confirmed bacteremia, to characterize de-escalation practices, and to evaluate pharmacy involvement throughout the sepsis care process. <b>Methods:</b> We conducted a retrospective review of adult patients with community-onset sepsis and confirmed bacteremia who presented to the Emergency Department (ED) between 9/2022 and 5/2023 at our hospital. The primary outcome was the percent of patients with ineffective empiric antimicrobials. Secondary outcomes included time to de-escalation, sepsis outcomes, sepsis guidelines adherence, and pharmacy interventions. <b>Results:</b> 109 patients were included. Median Charlson Comorbidity Index (CCI) was 6 (IQR 3-8) and Pitt bacteremia score 0 (IQR 0-1). Median time to first antibiotic administration was 29 minutes (IQR 15-50). Ineffective empiric antimicrobials occurred in 13.7% of cases, with median time to effective antibiotics at 24 h. De-escalation occurred in 84% of cases. The median time for discontinuation was 2 days for antimicrobial coverage against MRSA and atypical organisms and 4 days for coverage against <i>P. aeruginosa</i>. Initial therapy adhered to guidelines in 70.6% of cases, with deviation primarily due to vancomycin administration in the absence of MRSA risk factors. Antibiotic-related pharmacy recommendations were made in 40% (n = 44/109) of ED patients and 96% (n = 105/109) of hospitalized patients. In-hospital mortality, ICU admission, 30-day infection related re-admission and <i>C. difficile</i> infection within 6 months were 8.3% (n = 9), 42.2% (n = 46), 8.3% (n = 9), and 1.8% (n = 2), respectively. <b>Conclusion:</b> Pharmacist involvement led to appropriate antimicrobial selection in the ED, effective de-escalation, and favorable sepsis outcomes.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"322-329"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145459101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Midodrine Initiation and Vasopressor Liberation in Patients With Septic Shock in a Community-Teaching Hospital.","authors":"Joel Kennedy, Alyssa Osmonson, Jessica A Starr, Sarah B Blackwell","doi":"10.1177/08971900251384131","DOIUrl":"10.1177/08971900251384131","url":null,"abstract":"<p><p><b>Purpose:</b> In observational trials, midodrine decreased vasopressor duration, length of stay (LOS), and mortality but not in randomized controlled trials. The goal of this study is to assess the efficacy and safety of using midodrine to wean intravenous (IV) vasopressors in patients with septic shock. <b>Materials and Methods:</b> This single-center, retrospective study was conducted at a 505-bed community teaching hospital between September 2021 and December 2022. Patients were ≥18 years of age with septic shock, admitted to the intensive care unit (ICU), required IV vasopressors for hemodynamic support, and demonstrated clinical stability. Outcomes were compared across patients receiving IV vasopressors with midodrine vs. IV vasopressors alone. <b>Results:</b> Among 139 patients, midodrine was associated with increased time to IV vasopressor discontinuation, 5.5 ± 6.5 days vs. 2.4 ± 1.6 days (mean difference 3.1, 95% confidence interval 1.5 to 4.7, <i>P</i> = 0.0003). In patients started on midodrine within 48 hours of stability, time to IV vasopressor discontinuation was similar to the vasopressor alone cohort. Secondary outcomes including ICU and hospital LOS after vasopressor initiation, ICU and in-hospital mortality, and ICU readmission were similar between groups. Twenty patients were discharged from the hospital on midodrine. Incident bradycardia was increased in the midodrine group, but hypertension was similar between groups. <b>Conclusions:</b> Patients in the midodrine group exhibited a longer time to vasopressor discontinuation; however, this difference was only apparent in those with midodrine initiation more than 48 hours after hemodynamic stability in a post-hoc subgroup analysis. These outcomes may be attributed to midodrine being used as salvage therapy.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"280-286"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Publications on Infectious Diseases Pharmacotherapy in 2024.","authors":"Lauren Lee, Yao-Hsuan Huang, Hiba Al Shaikhli, Parijat Billah, Nhi Nguyen, Jamie Thomas, Ahmed Zaki, Kevin Lin","doi":"10.1177/08971900251408307","DOIUrl":"10.1177/08971900251408307","url":null,"abstract":"<p><p><b>Purpose:</b> To provide a summarization of the most significant infectious diseases (ID) pharmacotherapy articles published in peer-reviewed literature in 2024. <b>Summary:</b> Members of the Houston Infectious Diseases Network (HIDN) nominated notable articles providing significant contributions to ID pharmacotherapy in 2024. Article nominations included those pertaining to general ID and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) pharmacotherapy in 2024. To aid selection of the most significant articles in 2024, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP). Out of the 21 total articles nominated by HIDN/SIDP members, 19 pertained to general ID pharmacotherapy, and 2 had pertained to HIV/AIDS pharmacotherapy. Of the SIDP members who participated in the survey, 185 voted for the top 10 general ID pharmacotherapy articles and 46 votes were recorded for the top HIV/AIDS article. The most notable publications are summarized. <b>Conclusion:</b> This review provides a summary of the most recently published ID literature with aims to update clinicians on the current potential practice changing ID pharmacotherapy publications from 2024.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"257-270"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Intravenous Regular Insulin Dosing Strategies in Adults With Acute Hyperkalemia.","authors":"Michael O'Shea, Colleen Bond, Myroslava Sharabun, Darko Todorov","doi":"10.1177/08971900251394094","DOIUrl":"10.1177/08971900251394094","url":null,"abstract":"<p><p><b>Introduction:</b> Intravenous (IV) regular insulin treats acute hyperkalemia. No guideline recommendations exist on the appropriate dose to be administered to maximize safety and efficacy. <b>Objectives:</b> The objective of this study was to evaluate the safety and efficacy of IV regular insulin in patients who received 5 units of IV regular insulin to any dose greater than 5 units for acute hyperkalemia treatment. <b>Methods:</b> This was a single-center, retrospective, observational, cohort study. Patients were included if they were at least 18 years old, received greater than or equal to 5 units IV regular insulin, had pre-insulin potassium greater than or equal to 5.1 mEq/L and blood glucose measured within three hours before and 12 hours after insulin administration. The primary outcome was the incidence of hypoglycemia within 12 hours of insulin administration. <b>Results:</b> Eight-hundred and ninety-six charts were reviewed and 290 patients were included; 126 patients received 5 units and 164 patients received more than 5 units of IV regular insulin. Six patients (4.7%) who received 5 units experienced hypoglycemia compared to 23 patients (14%) who received greater than 5 units (<i>P</i> = 0.0014). Twenty-six of 29 (90%) who experienced hypoglycemia had renal impairment. Groups had a similar baseline mean potassium of 5.9 mEq/L (<i>P</i> = 0.32) and follow-up mean potassium of 5.3 mEq/L (<i>P</i> = 0.87). <b>Conclusion:</b> Patients who received 5 units of IV regular insulin had a lower incidence of hypoglycemia with a similar reduction in serum potassium when compared to patients who received doses greater than 5 units.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"303-308"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145377689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End User Adaptation Experiences, Implementation Strategies, and Lessons Learned With the VIONE Medication Optimization and Safe Deprescribing Project in the Federal Health System.","authors":"Kimberly Dickerson, Shira Winter, Saraswathy Battar, Christopher Sedgwick, Ashleigh Wallace-Lacey, Leah Satlak, Kayley Perkins, Mary Thoennes, Megan Fenney, Keilana Fisher, Dawn Currie, Janin Monterrey, William Hung","doi":"10.1177/08971900251383990","DOIUrl":"10.1177/08971900251383990","url":null,"abstract":"<p><p><b>Purpose:</b> There is extensive evidence linking Potentially Inappropriate Medication (PIM) use and adverse health outcomes. The VIONE core team and VA multidisciplinary partners created, implemented and disseminated the VIONE methodology across VA sites nationwide to facilitate and track deprescribing, through coaching, medical informatics and integration with the electronic health record. The purpose of this article is to report 3 sites in the federal health system (2 VA and 1 Indian Health Services) unique experiences of implementing and adapting VIONE locally while maintaining fidelity to fundamental VIONE intervention strategies. <b>Methods:</b> Three VA sites reported experiences of implementing VIONE, including an overview of the clinical workflow, clinicians involved, facilitators and barriers of implementation, and results. <b>Results:</b> The VIONE intervention was adapted for site-specific implementation. Personnel included trainees, clinical pharmacists, and home based primary care programs. Local and national dashboards were used to identify Veterans at high risk for polypharmacy and to track deprescribing. Implementation remained consistent with the VIONE core characteristics and facilitated education and conversations about medications with patients and caregivers. Adaptations were made at each site to meet that site's needs. Implementation resulted in safe deprescribing practices and staff empowerment with significant cost savings. <b>Conclusion:</b> The VIONE methodology and tools are adaptable across clinical settings with inherent flexibility to local workflows and practice preferences by end users. VIONE presents a standardized, easy-to-use method for promoting medication review for older adults. Further evaluation may help identify best practices to promote positive outcomes related to deprescribing and reducing polypharmacy in older adults.</p>","PeriodicalId":16818,"journal":{"name":"Journal of pharmacy practice","volume":" ","pages":"287-296"},"PeriodicalIF":1.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}